Novartis Ag (NVS) Research & Development (2009 - 2026)

Novartis Ag has disclosed Research & Development across 18 years of filings, most recently posting -$2.8 billion for Q2 2026.

• In Q2 2026, Research & Development fell 4.4% year-over-year to -$2.8 billion; the TTM figure through Jun 2026 stood at -$13.6 billion (up 7.1% YoY), while the FY2025 annual figure was -$11.2 billion, down 11.75% from the prior year.
• Research & Development came in at -$2.8 billion for Q2 2026 at Novartis Ag, down from -$2.7 billion in the prior quarter.
• In the past five years, Research & Development ranged from a high of -$2.3 billion in Q2 2023 to a low of -$8.8 billion in Q4 2023.
• Average Research & Development over 5 years is -$3.6 billion, with a median of -$2.7 billion recorded in 2023.
• Year-over-year, Research & Development sank 54.41% in 2023 and soared 39.06% in 2024.
• Over 5 years, Research & Development stood at -$7.0 billion in 2022, then slipped by 26.57% to -$8.8 billion in 2023, then grew by 18.45% to -$7.2 billion in 2024, then gained by 29.07% to -$5.1 billion in 2025, then jumped by 44.1% to -$2.8 billion in 2026.
• Per Business Quant data, the three most recent Research & Development figures were -$2.8 billion in Q2 2026, -$2.7 billion in Q1 2026, and -$5.1 billion in Q4 2025.